BNP Paribas Financial Markets Increases Stake in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)

BNP Paribas Financial Markets increased its position in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEOFree Report) by 184.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,541 shares of the company’s stock after buying an additional 3,591 shares during the period. BNP Paribas Financial Markets’ holdings in Lexeo Therapeutics were worth $50,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Bank of New York Mellon Corp grew its holdings in Lexeo Therapeutics by 12.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 31,806 shares of the company’s stock worth $510,000 after acquiring an additional 3,483 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Lexeo Therapeutics by 37.3% during the 2nd quarter. Rhumbline Advisers now owns 13,357 shares of the company’s stock worth $214,000 after purchasing an additional 3,627 shares during the last quarter. Values First Advisors Inc. acquired a new position in shares of Lexeo Therapeutics during the third quarter worth $67,000. Finally, Charles Schwab Investment Management Inc. increased its holdings in Lexeo Therapeutics by 107.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 63,874 shares of the company’s stock valued at $577,000 after buying an additional 33,013 shares during the last quarter. 60.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CEO Richard Nolan Townsend sold 5,000 shares of the company’s stock in a transaction on Thursday, October 10th. The shares were sold at an average price of $8.10, for a total value of $40,500.00. Following the completion of the sale, the chief executive officer now owns 120,695 shares in the company, valued at $977,629.50. This represents a 3.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 10,000 shares of company stock worth $80,550 in the last quarter. 4.50% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on LXEO. Leerink Partners decreased their price target on Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a report on Wednesday, November 13th. Chardan Capital boosted their target price on Lexeo Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Finally, HC Wainwright upped their price target on Lexeo Therapeutics from $21.00 to $23.00 and gave the company a “buy” rating in a report on Thursday, November 14th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $23.80.

Check Out Our Latest Stock Analysis on LXEO

Lexeo Therapeutics Stock Performance

Shares of LXEO stock opened at $6.04 on Friday. The stock’s 50-day moving average is $7.95 and its two-hundred day moving average is $11.05. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.95 and a current ratio of 5.95. Lexeo Therapeutics, Inc. has a 1 year low of $5.77 and a 1 year high of $22.33. The firm has a market cap of $199.72 million and a price-to-earnings ratio of -1.91.

Lexeo Therapeutics Profile

(Free Report)

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.

See Also

Institutional Ownership by Quarter for Lexeo Therapeutics (NASDAQ:LXEO)

Receive News & Ratings for Lexeo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexeo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.